We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Corning® Launches Videodrop, Revolutionizing Real-Time Nanoparticle Detection and Analysis

Nanoparticles.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Corning Incorporated (NYSE: GLW) announced the launch of Corning® Videodrop, an optical technology that applies the principles of interferometric microscopy to quantify the size and concentration of nanoparticles. The latest addition to the company’s growing suite of bioprocessing technology, Videodrop can analyze a solution in less than 60 seconds, and requires only a single 5-10 µl drop of sample material for testing.


The technology is capable of collecting a physical titer of viral vectors such as lentivirus, retrovirus, adenovirus, and extracellular vesicles (EVs) in the range of 80-500 nanometers. Once a sample is loaded, the processing algorithm detects and tracks nanoparticles to quantify the concentration and size distribution without the need for labeling. Videodrop can be used as an in-process control throughout the purification process.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“Videodrop is easy to use, fast, and reliable. Sample prep is also easy, being label free, and its operation is seamless thanks to its intuitive software interface,” said Chris Suarez, PhD, Sr. Manager, Scientific Applications and Support, Americas at Corning Life Sciences.


Not only can these efficiencies reduce overall costs, but Corning anticipates that this technology will support a variety of industry needs, including advancements in cell and gene therapy and vaccine production.


“We’re excited to extend our bioprocessing portfolio with our first solution that directly benefits our downstream customers,” said Janice Simler, PhD, Director of Business Operations for Bioproduction at Corning Life Sciences. “Our goal is to build out technology platforms across the whole workflow, expanding our impact as a valued partner throughout the drug development process.”